Das Medizinportal
Menü

Literatur:

Kurzübersicht zur modernen Diagnostik des malignen Melanoms

Chr. Kellner, H. Segert, Th. Gambichler; Bochum (S. 9-12)

  1. Pellacani G, Cesinaro A, Seidenari S: Reflectance-mode confocal microscopy of pigmented skin lesions – improvement in melanoma diagnostic specificity. J Am Acad Dermatol 2005;53,6:979-85
  2. Gerger A, Koller S, Weger W, et al. Sensitivity and specificity of confocal laser-scanning microscopy for in vivo diagnosis of malignant skin tumors. Cancer 2006;107:193-200
  3. Pellacani G, Guitera P, Longo C, Avramidis M, Seidenari S, Menzies S: The Impact of In Vivo Reflectance Confocal Microscopy for the Diagnostic Accuracy of Melanoma and Equivocal Melanocytic Lesions. J Invest Dermatol 2007; doi: 10.1038/sj.jid.5700993
  4. Guitera P, Pellacani G, Crotty KA, et al. The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. J Invest Dermatol 2010;130(8):2080-91
  5. Rajadhyaksha M, Gonzalez S, Zavislan JM, Anderson RR, Web RH. In vivo confocal laser microscopy of human skin II: advances in instrumentation and comparison with histology. J Invest Dermatol 1999;113:293-303 
  6. Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH, Anderson RR: In vivo confocal scanning laser microscopy of human skin: melanin provides strong contrast. J Invest Dermatol 1995;104:946-52
  7. Reflectance Confocal Microscopy of Cutaneous Tumors, An Atlas with Clinical, Dermoscopic and Histological Correlations; Edited by González S., Gill M., Halpern A.C., informa healthcare, London 2008
  8. Pellacani G, Longo C, Malvehy J, Puig S, Carrera C, Segura S, Bassoli S, Seidenari S: In Vivo Confocal Microscopic and Histopathologic Correlations of Dermoscopic Features in 202 Melanocytic Lesions. Arch Dermatol. 2008; 144(12):1597-1608
  9. A. Kardynal, M. Olszewska, Modern non-invasive diagnostic techniques in the detection of early cutaneous melanoma, Journal of dermatological case reports, 8 (2014) 1-8.
  10. Halpern A, Rajadhyaksha M, Toledo-Crow R. Bringing histology to the bedside. J Invest Dermatol 2005;124;8-10
  11. www.awmf.org/uploads/tx_szleitlinien/013076l_S1_Konfokale_Lasermikroskopie_2011-07_01.pdf
  12. Fercher AF, Hitzenberger CK, Drexler W et al. In vivo optical coherence tomography. Am J Ophtalmol 1993; 116: 113-4
  13. Fercher AF, Mengedoht K, Werner W. Eye-length measurement by interferometry with partially coherent light. Opt Lett 1988;13; 186-8
  14. Huang D, Swanson EA, Lin CP et al. Optical coherence tomography. Science 1991;254;1178-81
  15. Welzel J, Lankenau E, Birngruber R, Engelhardt R. Optical coherence tomography of the human skin. J Am Acad Dermatol 1997; 37; 958-63
  16. Gambichler T, Jaedicke V, Terras S. Optical coherence tomography in dermatology: technical and clinical aspects. Arch Dermatol Res 2011;303:457-73.
  17. A. Kardynal, M. Olszewska, Modern non-invasive diagnostic techniques in the detection of early cutaneous melanoma, Journal of dermatological case reports, 8 (2014) 1-8.
  18. Welzel J. Optical coherence tomography in dermatology: a review. Skin Res Technol 2001;7:1-9.
  19. Hinz T, Ehler LK, Hornung T, Voth H, Fortmeier I, Maier T, et al. Preoperative Characterization of Basal Cell Carcinoma Comparing Tumour Thickness Measurement by Optical Coherence Tomography, 20-MHz Ultrasound and Histopathology. Acta Derm Venereol. 2012 Mar;92(2):132-7.?
  20. Maier T, Braun-Falco M, Hinz T, Schmid-Wendtner MH, Ruzicka T, Berking C. Morphology of basal cell carcinoma in high definition optical coherence tomography: en-face and slice imaging mode, and comparison with histology. J Eur Acad Dermatol Venereol. 2012;doi: 10.1111/j.1468-3083.2012.04551.x. [Epub ahead of print]
  21. Mogensen M, Jaergensen TM, Nurnberg BM, Morsy HA, Thomsen JB, Thrane L, et al. Assessment of optical coherence tomography imaging in the diagnosis of non-melanoma skin cancer and benign lesions versus normal skin: observer-blinded evaluation by dermatologists and pathologists. Dermatol Surg 2009;35(6):965-72).
  22. T. Gambichler, M.H. Schmid-Wendtner, I. Plura, P. Kampilafkos, M. Stucker, C. Berking, T. Maier, A multicentre pilot study investigating high-definition optical coherence tomography in the differentiation of cutaneous melanoma and melanocytic naevi, Journal of the European Academy of Dermatology and Venereology : JEADV, (2014).
  23. Coleman AJ, Richardson TJ, Orchard G, Uddin A, Choi MJ, Lacy KE. Histological correlates of optical coherence tomography in non-melanoma skin cancer. Skin Res Technol. 2013 Feb;19(1):10-9. doi: 10.1111/j.1600-0846.2012.00626.x. Epub 2012 Jun 28.
  24. Banzhaf CA, Themstrup L, Ring HC, Mogensen M, Jemec GB. Optical coherence tomography imaging of non-melanoma skin cancer undergoing imiquimod therapy. Skin Res Technol. 2014 May;20(2):170-6. doi: 10.1111/srt.12102. Epub 2013 Sep 16.
  25. Aberg P, Birgersson U, Elsner P, Mohr P, Ollmar S. Electrical impedance spectroscopy and the diagnostic accuracy for malignant melanoma. Exp. Dermatol. 2011 Aug;20(8):648-52. doi: 10.1111/j.1600-0625.2011.01285.x. Epub 2011 May 4.
  26. Mohr P, Birgersson U, Berking C, Henderson C, Trefzer U, Kemeny L, Sunderkötter C, Dirschka T, Motley R, Frohm-Nilsson M, Reinhold U, Loquai C, Braun R, Nyberg F, Paoli J. Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanoma. Skin Res Technol. 2013 May;19(2):75-83. doi: 10.1111/srt.12008. Epub 2013 Jan 27.
  27. Monheit G, Cognetta AB, Ferris L, et al. The performance of MelaFind: a prospective multicenter study. Arch Dermatol. 2011;147(2):188-194.
  28. Gutkowicz-Krusin D, Elbaum M, Jacobs A, et al. Precision of automatic measurements of pigmented skin lesion parameters with a MelaFind(TM) multispectral digital dermoscope. Melanoma Res. 2000;10(6):563-570.
  29. www.melafind.de/wp-content/uploads/M100-BR-005RevA-_PhysDetail_f_rev_lowres.pdf
  30. www.melafind.de/wp-content/uploads/M100-BR-005RevA-_PhysDetail_f_rev_lowres.pdf
  31. A. Hauschild, S.C. Chen, M. Weichenthal, A. Blum, H.C. King, J. Goldsmith, D. Scharfstein, D. Gutkowicz-Krusin, To excise or not: impact of MelaFind on German dermatologists' decisions to biopsy atypical lesions, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 12 (2014) 606-614.
  32. Romano E, Schwartz GK, Chapman PB et al.: Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 12:913-922, 2012. DOI: DOI:10.1016/S1470-2045(10)70274-6
  33. Dr. K.G. Griewank : Molekulare Diagnostik bei melanozytären Tumoren. Der Pathologe, February 2015, Volume 36, Issue 1, pp 30-36 
  34. Gaiser MR, Stadler R, Schirmacher P, Dietel M, Enk A. Mutationsanalysen im malignen Melanom. Article first published online: 30 MAY 2013. DOI: 10.1111/ddg.12070
  35. Davies H, Bignell GR, Cox C et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417:949–954
  36. Hou P, Liu D, Xing M. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle. 2007 Feb 1;6(3):377-9. Epub 2007 Feb 5.
  37. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. GENES & DEVELOPMENT 20:2149–2182 
  38. Arlo J. Miller, M.D., Ph.D., and Martin C. Mihm, Jr., M.D. Melanoma. N Engl J Med 2006; 355:51-65July 6, 2006DOI: 10.1056/NEJMra052166
  39. Omholt K1, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003 Dec 15;9(17):6483-8.
  40. Lovly CM1, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. PLoS One. 2012;7(4):e35309. doi: 10.1371/journal.pone.0035309. Epub 2012 Apr 20. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
  41. Nat Rev Cancer. 2004 Dec;4(12):937-47. Targeting the mitogen-activated protein kinase cascade to treat cancer. Sebolt-Leopold JS1, Herrera R.
  42. Pratilas CA1, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24. doi: 10.1073/pnas.0900780106. Epub 2009 Feb 27.
  43. Kirkwood JM1, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012 Jan 15;18(2):555-67. doi: 10.1158/1078-0432.CCR-11-1491. Epub 2011 Nov 2.
  44. Infante JR1, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug;13(8):773-81. doi: 10.1016/S1470-2045(12)70270-X. Epub 2012 Jul 16.
  45. van 't Veer LJ1, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, Schrier PI, Bos JL. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol. 1989 Jul;9(7):3114-6.
  46. Edlundh-Rose E1, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, Lundeberg J. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 2006 Dec;16(6):471-8.
  47. Goel VK1, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006 Jan;126(1):154-60.
  48. Devitt B1, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, Dobrovic A, McArthur G. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011 Aug;24(4):666-72. doi: 10.1111/j.1755-148X.2011.00873.x. Epub 2011 Jun 22.
  49. Russo AE1, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F, Malaponte G. Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol. 2009 Jun;34(6):1481-9.
  50. Saldanha G1, Potter L, Daforno P, Pringle JH. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res. 2006 Aug 1;12(15):4499-505.
  51. Grichnik JM1. Kit and melanocyte migration. J Invest Dermatol. 2006 May;126(5):945-7.
  52. Curtin JA1, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma J. Clin Oncol. 2006 Sep 10;24(26):4340-6. Epub 2006 Aug 14.
  53. Wu H1, Goel V, Haluska FG.. PTEN signaling pathways in melanoma. Oncogene. 2003 May 19;22(20):3113-22.
  54. Stahl JM1, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP.. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003 Jun 1;63(11):2881-90.
  55. Tsao H1, Mihm MC Jr, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol. 2003 Nov;49(5):865-72.
  56. Palmieri G1, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. Main roads to melanoma. J Transl Med. 2009 Oct 14;7:86. doi: 10.1186/1479-5876-7-86.
  57. Liaw D1, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997 May;16(1):64-7.
  58. Tsao H1, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004 Feb;122(2):337-41.
  59. Mirmohammadsadegh A1, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, Hengge UR. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006 Jul 1;66(13):6546-52.
  60. Zhou XP1, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol. 2000 Oct;157(4):1123-8.
  61. Van Raamsdonk CD1, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O'Brien J, Bastian BC. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010 Dec 2;363(23):2191-9. doi: 10.1056/NEJMoa1000584. Epub 2010 Nov 17.
  62. Singh AD1, Bergman L, Seregard S.Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005 Mar;18(1):75-84, viii. 

Gewebeschonende Entfernung von Hauttumoren

K. Schweinzer, L. Kofler, H.-M. Häfner;  Tübingen (S. 14-16)

 

  1. Trakatelli, M., et al., Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol, 2007. 156 Suppl 3: p. 1-7.
  2. Leverkus, M., Malignant epithelial tumors: Part I. Pathophysiology and clinical features. J Dtsch Dermatol Ges, 2012. 10(7): p. 457-71; quiz 472.
  3. Breuninger, H., et al., Brief S2k guidelines--Cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges, 2013. 11 Suppl 3: p. 37-45, 39-47.
  4. Hauschild, A., et al., Brief S2k guidelines--Basal cell carcinoma of the skin. J Dtsch Dermatol Ges, 2013. 11 Suppl 3: p. 10-5, 11-6.
  5. Eberle, F.C., et al., Cosmetic results of histographically controlled excision of non-melanoma skin cancer in the head and neck region. J Dtsch Dermatol Ges, 2005. 3(2): p. 109-12.
  6. Hafner, H.M., et al., 3D histology-guided surgery for basal cell carcinoma and squamous cell carcinoma: recurrence rates and clinical outcome. Int J Oral Maxillofac Surg, 2011. 40(9): p. 943-8.
  7. Mohs, F.E., Chemosurgery: a method for the microscopically controlled excision of cancer of the skin and lips. Geriatrics, 1959. 14(2): p. 78-88.
  8. Breuninger, H., Histologic control of excised tissue edges in the operative treatment of basal-cell carcinomas. J Dermatol Surg Oncol, 1984. 10(9): p. 724-8.
  9. Breuninger, H. and G. Schaumburg-Lever, Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohs' technique. J Pathol, 1988. 154(2): p. 167-71.
  10. Richtig, E., et al., Follow-up of actinic keratoses after shave biopsy by in-vivo reflectance confocal microscopy--a pilot study. J Eur Acad Dermatol Venereol, 2010. 24(3): p. 293-8.
  11. Hafner, H.M., et al., [Surgical treatment of epithelial skin tumors and their precursors]. Hautarzt, 2013. 64(8): p. 558-66.
  12. Moehrle, M., et al., Conventional histology vs. three-dimensional histology in lentigo maligna melanoma. Br J Dermatol, 2006. 154(3): p. 453-9.
  13. Lichte, V., et al., Acral lentiginous melanoma: conventional histology vs. three-dimensional histology. Br J Dermatol, 2009. 160(3): p. 591-9.
  14. Schulz, C., et al., [Local recurrence and survival in acral lentiginous melanoma comparing 3D histology and conventional histology]. J Dtsch Dermatol Ges, 2014. 12(10): p. 881-90.
  15. Hafner, H.M., et al., 3D-Histological evaluation of surgery in dermatofibrosarcoma protuberans and malignant fibrous histiocytoma: differences in growth patterns and outcome. Eur J Surg Oncol, 2008. 34(6): p. 680-6.
  16. Boehringer, A., et al., Extramammary Paget's disease: extended subclinical growth detected using three-dimensional histology in routine paraffin procedure and course of the disease. Dermatol Surg, 2011. 37(10): p. 1417-26.

Moderne medikamentöse Therapieoptionen beim malignen Melanom

C. Bender, J.C. Hassel; Heidelberg  (s. 17-20)

 

  1. Krebs in Deutschland 2009/2010. 2013  06.05.2015]; 9. Ausgabe:[Available from: www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsB/KID2013.pdf%3F__blob%3DpublicationFile
  2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. The New England journal of medicine. 2004;351:998-1012.
  3. Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science. 2014;346:945-9.
  4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
  5. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. The New England journal of medicine. 2005;353:2135-47.
  6. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999;400:468-72.
  7. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24:4340-6.
  8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011;364:2507-16.
  9. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-65.
  10. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. The New England journal of medicine. 2014;371:1877-88.
  11. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer treatment reviews. 2003;29:241-52.
  12. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. British journal of cancer. 2003;89:1620-6.
  13. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer. 2010;116:4139-46.
  14. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010;363:711-23.
  15. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet. 2014;384:1109-17.
  16. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England journal of medicine. 2013;369:134-44.
  17. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2015.
  18. Postow MA. Managing immune checkpoint-blocking antibody side effects. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2015;35:76-83.
  19. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. The New England journal of medicine. 2015;372:320-30.
  20. Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer immunology, immunotherapy : CII. 2014;63:449-58.
  21. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England journal of medicine. 2014;371:2189-99.
  22. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. The New England journal of medicine. 1988;319:1676-80.
  23. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Journal of the National Cancer Institute. 1994;86:1159-66.
  24. Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Human gene therapy. 2008;19:496-510.
  25. Schadendorf D, Keilholz U. Systemische Therapie des metastasierten Melanoms.  Management des Melanoms: Springer Berlin Heidelberg; 2006. p. 285-95.
  26. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. The Lancet Oncology. 2003;4:748-59.
  27. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. The Lancet Oncology. 2015;16:522-30.

ASCO-Update: Neuroendokrine Tumoren

C. Fottner, M. M. Weber; Mainz (S. 26-28)

 

  1. Fottner C, Miederer M, Musholt TJ, Weber MM Neuroendokriner Neoplasien des Gastrointestinaltrakts – Diagnostik und interdisziplinäre Therapie. Best practice Onkologie 2013 6(8):6-14
  2. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group.Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63.
  3. Caplin ME, Pavel M, ?wik?a JB, Phan AT, Raderer M, Sedlá?ková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. 
  4. Caplin ME et al. Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study. J Clin Oncol 32:5s, 2014 (suppl; abstr 4107)
  5. Dasari A. et al. Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study. J Clin Oncol 33, 2015 (suppl; abstr 4104)
  6. Pavel ME et al. Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias. J Clin Oncol 33, 2015 (suppl; abstr 4091)
  7. Yao JC et al. SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol 33, 2015 (suppl; abstr 4004)
  8. Hobday TJ et al. Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor (PNET). J Clin Oncol 33, 2015 (suppl; abstr 4096)
  9. Kulke MH et al. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).J Clin Oncol 33, 2015 (suppl; abstr 4005)
  10. Salazar R. et al. Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET). J Clin Oncol 33, 2015 (suppl; abstr 4102)